Cushing’s syndrome: epidemiology and developments in disease management

Abstract: Cushing’s syndrome is a rare disorder resulting from prolonged exposure to excess glucocorticoids. Early diagnosis and treatment of Cushing’s syndrome is associated with a decrease in morbidity and mortality. Clinical presentation can be highly variable, and establishing the diagnosis can often be difficult. Surgery (resection of the pituitary or ectopic source of adrenocorticotropic hormone, or unilateral or bilateral adrenalectomy) remains the optimal treatment in all forms of Cushing’s syndrome, but may not always lead to remission. Medical therapy (steroidogenesis inhibitors, agents that decrease adrenocorticotropic hormone levels or glucocorticoid receptor antagonists) and pituitary radiotherapy may be needed as an adjunct. A multidisciplinary approach, long-term follow-up, and treatment modalities customized to each individual are essential for optimal control of hypercortisolemia and management of comorbidities.

Keywords: Cushing’s syndrome, hypercortisolism, treatment, epidemiology

Introduction
Cushing’s syndrome is a rare disorder caused by prolonged exposure to excess glucocorticoids. The clinical presentation is highly variable. While the diagnosis can be straightforward in florid cases, establishing the diagnosis can be challenging in cases with mild hypercortisolism and subtle clinical features, especially given the overlap in symptoms in individuals with and without the syndrome. Here, we discuss the epidemiology, diagnosis, and advances in management of endogenous Cushing’s syndrome.

Epidemiology and prognosis
Administration of supraphysiologic doses of glucocorticoids is the most common cause of Cushing’s syndrome (exogenous or iatrogenic Cushing’s syndrome). As glucocorticoids are used to treat inflammatory, autoimmune, and neoplastic disorders, a detailed medication history is essential. Although the oral route is most commonly associated with iatrogenic Cushing’s syndrome, any mode of delivery, including inhaled, topical, or injectable glucocorticoids, should be sought.

Endogenous Cushing’s syndrome is rare, with an incidence of 0.7–2.4 per million population per year. 

A population-based study from Denmark reported a diagnosis of Cushing’s syndrome in 166 patients over an 11-year period (1985–1995), yielding an incidence of two cases per million inhabitants per year.

Of the 139 patients with nonmalignant disease, 23 (16.5%) died during follow-up (median 8 years), yielding a standard mortality ratio of 3.7 (95% confidence interval 2.3–5.3), with the highest mortality during the first year after initial presentation. Eight deaths occurred before
initiation of treatment. Causes of death included suicide (n=1), cardiac rupture (n=1), stroke (n=1), and severe infections (n=3; peritonitis, septicemia, and pneumonia). The cause of death could not be ascertained in two patients. A similar study from Spain reported 49 cases of Cushing’s syndrome over 18 years, yielding an incidence of 2.4 cases per million inhabitants per year, with a standard mortality ratio of 3.8.4 Although the mortality risk decreases with remission of hypercortisolism,5 it is not equivalent to that of the general population. Several studies have shown that increased morbidity, especially related to cardiovascular disease, persists for several years after biochemical remission.6–9 Furthermore, varying criteria for remission of hypercortisolism across studies make it difficult to interpret these outcome measures accurately.

Although population-based studies demonstrate a low incidence of endogenous Cushing’s syndrome, more evaluations of patients with uncontrolled diabetes mellitus or hypertension suggest that this may be an underestimation.10–13 Leibowitz et al screened 90 obese subjects with uncontrolled diabetes mellitus (hemoglobin A1c >9%), and found three (3.3%) to have Cushing’s syndrome.10 Similarly, Catargi et al diagnosed Cushing’s syndrome in four (2%) of 200 obese subjects with uncontrolled diabetes mellitus.11 However, this reported prevalence of 2%–5% was not confirmed in other studies.14–17 Also, an evaluation of 369 overweight and obese subjects with at least two other features of Cushing’s syndrome did not identify any with Cushing’s syndrome, but 84 subjects had at least one abnormal screening test result.18 Widespread screening for Cushing’s syndrome in overweight individuals or patients with type 2 diabetes mellitus is therefore not recommended.18,19 Instead, a case-finding approach in patients with other features of Cushing’s syndrome or uncontrolled diabetes or hypertension despite appropriate treatment may be indicated.19

Currently, extensive use of computed tomography (CT) and magnetic resonance imaging (MRI) scans has led to an increasing number of incidentally found adrenal masses. The prevalence of these adrenal “incidentalomas” increases from 0.2% to 7% with increasing age.20–22 “Subclinical” or subtle Cushing’s syndrome has been reported in 5%–10% of these patients, who represent a population in which Cushing’s syndrome is more common.22,23

**Classification of Cushing’s syndrome**

Traditionally, endogenous Cushing’s syndrome is classified as adrenocorticotropic hormone (ACTH)-dependent or ACTH-independent. ACTH-dependent Cushing’s syndrome accounts for 80%–85% of cases. Of these, 75%–80% are due to ACTH production from a pituitary adenoma (Cushing’s disease [CD]), 15%–20% are due to ACTH production from nonpituitary tumors (ectopic ACTH syndrome [EAS]) and <1% are caused by corticotropin-releasing hormone (CRH)-producing tumors.1,23 Most pituitary tumors are sporadic, resulting from monoclonal expansion of a single mutated cell. Rarely, they may occur as part of a genetic syndrome, the most common being multiple endocrine neoplasia type 1 and familial isolated pituitary adenomas. Ectopic ACTH secretion most often derives from small-cell carcinoma of the lung or pulmonary carcinoid tumor. Other causes include pancreatic neuroendocrine tumors (NETs), thymic NETs, medullary thyroid cancer, and pheochromocytoma.24

ACTH-independent Cushing’s syndrome accounts for 15%–20% of endogenous Cushing’s syndrome in adults; 90% are unilateral adrenal tumors. Of these, adenomas are the cause in ~80% of the cases, while the others are adrenocortical carcinoma.25 Rare adrenal causes of Cushing’s syndrome include macronodular adrenal hyperplasia, primary pigmented nodular adrenal disease (sporadic or as part of Carney’s complex) and McCune–Albright syndrome. In a recent study, Louis et al described intra-adrenal production of ACTH and paracrine regulation of cortisol secretion in 30 cases of bilateral macronodular adrenal hyperplasia.26 Proopiomelanocortin messenger ribonucleic acid expression was detected in all hyperplastic tissue samples and ACTH was detected in steroidogenic cell clusters throughout adrenal tissue specimens. ACTH levels were also found to be higher in adrenal venous samples of two patients compared to the periphery.26 These findings bring into question the traditional classification of “ACTH-independent Cushing’s syndrome”.27

In childhood and adolescence, as in adults, exogenous glucocorticoids are the most common cause of Cushing’s syndrome. The causes of endogenous Cushing’s syndrome in children are similar to those in adults, with some differences. Cushing’s syndrome in infancy is commonly associated with McCune–Albright syndrome, adrenocortical tumors are usually the cause in children less than 5–7 years of age, CD is the commonest cause after 7 years of age, and EAS is extremely rare.28

**Clinical features of Cushing’s syndrome**

The clinical presentation of Cushing’s syndrome is variable (Table 1). It is influenced by age and sex and the severity and duration of the disease.1,24,28–31 No single sign or symptom is pathognomonic.
The clinical presentation of Cushing’s syndrome can vary by sex. Men with CD are more likely to present at a younger age with more florid clinical features. Violaceous striae, muscle weakness and atrophy, osteoporosis, and kidney stones are much more common. Gonadal dysfunction is common in both men and women, presenting as decreased libido, infertility, menstrual irregularity or amenorrhea in women, and erectile dysfunction in men. While CD has a female preponderance (female: male ratio 3:4:1), EAS is equally common in both sexes among the adult population. Unlike adults, pediatric CD is characterized by significant male preponderance in the prepubertal years. With increasing age, the sex distribution of CD equalizes toward puberty, with a trend toward female preponderance in adulthood.

Classically, patients with ectopic Cushing’s have severe hypercortisolism associated with a rapid onset of symptoms and a florid presentation, hypokalemia, and severe or opportunistic infections. However, these features reflect the severity of hypercortisolism, and can be seen in patients with CD. By contrast, the clinical presentation of many ACTH-secreting carcinoid tumors may be indistinguishable from that of CD, reflecting less extreme hypercortisolism.

Decreased bone mineral density, osteoporosis, and fractures are present in 50%–80% of patients with Cushing’s syndrome. After cure, bone mineral density improves, but additional specific treatment for fractures and related pain may be needed. Bone loss can be more severe in primary adrenal disease compared to CD. This may be related to a protective effect of the higher adrenal androgen levels in CD. Hypercortisolism is also associated with a decrease in brain volume, particularly the hippocampus, and related impairment in learning and short-term memory. Although psychiatric and cognitive symptoms improve after remission, many symptoms may persist.

Excess glucocorticoids have a catabolic effect on skeletal muscles, skin, and connective tissue. Increased protein wasting and type II muscle-fiber atrophy is associated with significant muscle weakness, with predominant involvement of the pelvic girdle musculature. Vertebral fractures, back pain, and depression further lead to decreased mobility and disuse muscle atrophy. A persistently impaired quality of life, primarily of the physical domain, and persistent muscle weakness have been documented even several years after remission.

Dyslipidemia (increased low-density lipoprotein, decreased high-density lipoprotein) and glucose intolerance occur in 45%–70% of patients. This reported prevalence

| Table 1 Clinical features of Cushing’s syndrome |
|-----------------------------|-----------------|
| Signs/symptoms              | Prevalence (%)  |
| General                     |                 |
| Obesity or weight gain      | 70–95           |
| Rounded face (moon face)    | 81–90           |
| Supraventricular/dorsocervical fat pads (buffalo hump) | 50 |
| Skin                        |                 |
| Hirsutism/alopecia          | 75              |
| Facial plethora             | 70–90           |
| Violaceous striae           | 44–50           |
| Acne                        | 20–35           |
| Easy bruising               | 35–65           |
| Gonads                      |                 |
| Menstrual irregularity      | 70–80           |
| Decreased libido            | 24–80           |
| Neuropsychiatric            |                 |
| Emotional lability/depression | 70–85         |
| Psychosis/mania             |                 |
| Cognitive dysfunction/short-term memory loss | |
| Musculoskeletal             |                 |
| Muscle weakness/atrophy     | 60–82           |
| Osteopenia or fractures     | 40–70           |
| Decreased linear growth in children | 70–80 |
| Metabolic                   |                 |
| Hypertension                | 70–85           |
| Glucose intolerance         | 45–70           |
| Hyperlipidemia              | 70              |
| Hepatic steatosis           | 20              |
| Nephrolithiasis             | 21–50           |

of glucose intolerance is likely an underestimate, as many patients with normal fasting glucose have underlying glucose intolerance, and not all patients with Cushing’s syndrome undergo glucose-tolerance testing. Hypertension (cortisol-mediated enhancement of vascular reactivity to vasoconstrictors and the mineralocorticoid effects of cortisol), though not invariably present, is frequently seen in patients with Cushing’s syndrome, with a prevalence of approximately 80%. Hepatic steatosis and increased visceral adipose tissue are common in patients with Cushing’s syndrome. These features of metabolic syndrome, along with a hypercortagal state, lead to an increased cardiovascular risk that may not return to baseline after successful treatment.

Diagnosis of Cushing's syndrome

Clinical suspicion in patients with multiple and progressive signs and symptoms suggestive of Cushing’s syndrome should provoke diagnostic testing. Screening may be considered in patients with other features of Cushing’s syndrome, particularly with poorly controlled diabetes or hypertension, or unexplained osteoporosis. Patients with an incidentally discovered adrenal mass should be evaluated.

It is important to differentiate between the pathological hypercortisolism of endogenous Cushing’s syndrome and that associated with pregnancy, glucocorticoid resistance, and pseudo-Cushing’s states like alcoholism, depression, severe obesity, anorexia nervosa, and bulimia. The hypercortisolism of pseudo-Cushing’s states is thought to be mediated via increased hypothalamic secretion of CRH. In contrast, hypothalamic CRH is suppressed in true Cushing’s syndrome.

Biochemical tests in Cushing’s syndrome are based on the cardinal features of increased endogenous secretion of cortisol, loss of normal feedback of the hypothalamic–pituitary–adrenal axis, and loss of the normal cortisol circadian rhythm. According to the 2008 Endocrine Society guidelines, the following tests should be used for the diagnosis of Cushing’s syndrome: 24-hour urinary free cortisol (UFC), late-night salivary cortisol, and/or a low-dose dexamethasone-suppression test (DST; 1 mg overnight or 2 mg/day over 48 hours). None of these tests has 100% diagnostic accuracy; each has its own caveats, and multiple tests are usually needed to establish the diagnosis (Table 2).

UFC is an index of circulating free (biologically active) cortisol. Unlike plasma cortisol, which measures total cortisol (bound and unbound), UFC results are not affected by factors that modulate the levels of corticosteroid-binding globulin (CBG). Inappropriate urine collection, increased fluid intake, and abnormal renal function can be associated with false-positive and -negative results. Review of urine volume and creatinine excretion can help assess the adequacy of urine collection. UFC values in Cushing’s syndrome are variable. Cushing’s syndrome is highly unlikely in the setting of three or more normal UFC levels, except in rare cases of cyclic Cushing’s syndrome. Values more than

### Table 2 Sensitivity, specificity, and caveats of screening tests for Cushing’s syndrome

<table>
<thead>
<tr>
<th>Test</th>
<th>Criteria</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Caveat (unreliable in)</th>
</tr>
</thead>
<tbody>
<tr>
<td>UFC</td>
<td>&gt;3× ULN</td>
<td>80%–98%</td>
<td>45%–98%</td>
<td>Improper collection</td>
</tr>
<tr>
<td>Late-night salivary cortisol</td>
<td>&gt;145 ng/dL</td>
<td>92%–100%</td>
<td>93%–100%</td>
<td>Improper collection, storage, licorice/chewing tobacco, smoking, aggressive tooth brushing</td>
</tr>
<tr>
<td>MN serum cortisol</td>
<td>&gt;7.5 μg/dL (awake)</td>
<td>91%–98%</td>
<td>92%–100%</td>
<td>Patient not resting/sleeping</td>
</tr>
<tr>
<td></td>
<td>&gt;1.8 μg/dL (sleeping)</td>
<td>100%</td>
<td>30%–62%</td>
<td>Not drawn from indwelling line</td>
</tr>
<tr>
<td>1 mg Overnight DST</td>
<td>Post-Dex F</td>
<td>91%–97%</td>
<td>80%–94%</td>
<td>Estrogen/mitotane (↑ CBG)</td>
</tr>
<tr>
<td></td>
<td>&gt;1.8 μg/dL</td>
<td>85%–90%</td>
<td>95%–99%</td>
<td>Nephrotic syndrome/cirrhosis (↓ CBG)</td>
</tr>
<tr>
<td></td>
<td>&gt;5 μg/dL</td>
<td></td>
<td></td>
<td>Dex metabolism/clearance (cimetidine, fluoxetine, diltiazem, renal insufficiency)</td>
</tr>
<tr>
<td>2-Day low-dose DST</td>
<td>Post-Dex F</td>
<td>91%–98%</td>
<td>70%–95%</td>
<td>Similar to 1 mg DST</td>
</tr>
<tr>
<td>Dex-CRH</td>
<td>Post-CRH F</td>
<td>98%–100%</td>
<td>60%–100%</td>
<td>Similar to DST</td>
</tr>
</tbody>
</table>

**Notes:** To convert plasma cortisol from μg/dL to nmol/L, multiply by 27.6. To convert salivary cortisol from ng/dL to nmol/L, multiply by 0.028. Data from Newell-Price et al, Nieman et al and de Castro and Moreira.

**Abbreviations:** CBG, corticosteroid-binding globulin; Dex, Dexamethasone; CRH, corticotropin-releasing hormone; DST, Dex-suppression test; f, cortisol; MN, midnight; ULN, upper limit of normal; UFC, 24-hour urine free cortisol.
three- to fourfold the upper limit of normal are generally diagnostic of Cushing’s syndrome.\(^1\)\(^{19}\)\(^{31}\)

DSTs rely on the loss of glucocorticoid negative-feedback inhibition of CRH and ACTH secretion. In the overnight test, 1 mg of dexamethasone is given at 11 pm, followed by measurement of fasting plasma cortisol between 8 and 9 am the next morning. In the 2-day test, 0.5 mg of dexamethasone is given every 6 hours (starting at 9 am) for 2 days, with cortisol measurement at the beginning and end of the test. A cortisol level of \(\leq 1.8 \mu g/dL\) (50 nmol/L) at the end of either test excludes Cushing’s syndrome (Table 2).\(^{19}\) Variable absorption and metabolism of dexamethasone can affect the results of the DSTs. Estrogen treatment and pregnancy can increase CBG levels, leading to false-positive DST results. For accurate results, estrogen treatment should be stopped for 4–6 weeks to allow CBG levels to return to baseline.\(^{119}\) Some (3%–8%) CD patients show suppression of cortisol levels below 1.8 \(\mu g/dL\) (50 nmol/L) on DST.\(^{1,16}\) Multiple repeated tests may be needed to establish the diagnosis in these cases.

Salivary cortisol, like UFC, measures free cortisol, and is therefore not affected by CBG levels. Diagnostic ranges vary between studies, due to the different assays and comparison groups used to set cutoff points.\(^{63}\) Salivary cortisol can be measured by immunoassay or liquid chromatography–tandem mass spectrometry (LC/MS-MS). Given the lower sensitivity of LC/MS-MS (as it may not measure cortisol metabolites/precursors), immunoassay remains the preferred methodology for screening of Cushing’s syndrome.\(^{67-69}\) Educating the patient on optimal timing of specimen collection while taking into account their normal sleep–wake cycle, as well as avoiding exciting or stressful experiences on the evening of the test, are important for an accurate salivary cortisol result. False-positive results can also be seen, due to contamination of the saliva sample with widely available nonprescription topical hydrocortisone creams and ointments. However, overall, ease of collection, stability at room temperature, and a greater than 90% sensitivity and specificity make it a highly useful test, especially in outpatients, children, and in assessment of cyclic Cushing’s syndrome.\(^{67-69}\) Midnight plasma cortisol levels also can be used for screening. A single sleeping midnight plasma cortisol level of less than 1.8 \(\mu g/dL\) (50 nmol/L) excludes active Cushing’s syndrome.\(^{70}\) A midnight plasma cortisol level, drawn while the patient is resting but not fully asleep, of more than 7.5 \(\mu g/dL\) (207 nmol/L) is a more specific cutoff, but can miss up to 7% cases of mild Cushing’s syndrome.\(^{71,72}\)

If the diagnosis remains unclear, dexamethasone-suppressed CRH stimulation (Dex-CRH) test\(^{73-74}\) or the desmopressin test\(^{75,76}\) can be performed to distinguish further between CD and pseudo-Cushing’s states. However, the exact diagnostic accuracy of these tests and the optimal cutoffs for diagnosis need further evaluation.\(^{77}\) Moreover, similarly to other dexamethasone tests, variable absorption and metabolism of dexamethasone, especially in the setting of concomitant use of other commonly prescribed medications, can affect the accuracy of the test.\(^{78}\) Recently, a prospective study of 73 patients with clinical features of hypercortisolism and an abnormal DST or UFC result reported a positive predictive value of 100% and a negative predictive value of 90% for the Dex-CRH test (sensitivity 94%, specificity 100%) using a 15-minute post-CRH cortisol cutoff of 3.2 \(\mu g/dL\) (87 nmol/L).\(^{79}\)

**Establishing the cause of Cushing’s syndrome**

Once the diagnosis of Cushing’s syndrome has been established, the next step is to differentiate between the three causes. Measurement of plasma ACTH levels is the initial step in the differential diagnosis. A two-site immunoradiometric assay is preferred over radioimmunoassay, because it better discriminates low or suppressed ACTH levels.\(^{80}\) To avoid falsely low results, ACTH levels should be measured on multiple occasions, and samples should be collected in prechilled ethylenediaminetetraacetic acid tubes, transported in an ice bath, and processed immediately.\(^1\) Values <5 pg/mL (1.1 pmol/L) suggest ACTH-independent Cushing’s syndrome. Imaging studies of the adrenal gland can then identify unilateral or bilateral lesions. The glands may appear normal in primary pigmented nodular adrenal disease. Patients with proven ACTH-independent hypercortisolism but normal adrenal imaging studies should undergo screening for exogenous glucocorticoids, assessment for other features of Carney’s complex, and possibly genetic testing for \textit{PRKAR1A} mutations.\(^{81}\) A paradoxical increase in glucocorticoid excretion in response to dexamethasone during the Liddle test (0.5 mg dexamethasone every 6 hours for 48 hours, followed by 2 mg every 6 hours for 48 hours) can further help identify patients with primary pigmented nodular adrenocortical disease.\(^{82}\) Recently, an inactivating germ-line mutation of \textit{ARMC5}, a putative tumor-suppressor gene, has been implicated in the development of primary bilateral macronodular hyperplasia.\(^{83-85}\) Patients with this mutation show familial clustering and bilateral disease, and often present with a more severe clinical phenotype. Genetic testing for this mutation may help in earlier diagnosis and better management of these cases.\(^{85}\)
An inappropriately normal or elevated ACTH level (>20 pg/mL, 4.4 pmol/L) is consistent with an ACTH-dependent form of Cushing’s syndrome. Patients with mild adrenal Cushing’s may not have suppressed ACTH levels. Moreover, recently, intra-adrenal production of ACTH has been reported in macronodular adrenal hyperplasia, although peripheral ACTH levels were suppressed. CRH stimulation and high-dose DSTs may help differentiate between adrenal and ACTH-dependent forms of Cushing’s syndrome when ACTH results are indeterminate.

Although there is significant overlap in ACTH levels between CD and EAS, extremely high levels (>500 pg/mL, 110 pmol/L) usually reflect EAS. Sex may help: 90% of cases of ACTH-dependent Cushing’s syndrome in women are caused by CD.

A pituitary MRI should be obtained in ACTH-dependent cases. A large mass (>6 mm) strongly suggests CD. However, ACTH-secreting pituitary tumors are usually small and may not be detected, even with newer, more advanced MRI techniques (spoiled gradient-recalled acquisition or dynamic MRI sequences) in 20%–58% of patients with CD. Moreover, ~10% of “healthy” individuals can have incidental pituitary lesions up to 6 mm in size. Differential diagnosis of ACTH-dependent Cushing’s syndrome can therefore be very challenging.

The high-dose DST (2 mg given every 6 hours for 48 hours, or the overnight test with a single 8 mg dose) is based on the concept that corticotrope adenomas arise clonally from normal cells and retain some sensitivity to glucocorticoid negative feedback, while ectopic ACTH-secreting tumors do not. In the overnight test, a greater than 69% suppression of cortisol levels following 8 mg of dexamethasone suggests a pituitary source of ACTH. Logistic regression modeling has shown that the diagnostic accuracy of this test is less than the pretest likelihood based on clinical features alone. Due to the poor diagnostic accuracy (~80%) of a high-dose DST, many endocrinologists do not recommend performing the test unless inferior petrosal sinus sampling (IPSS) is not available.

In the CRH-stimulation test, recombinant ovine or human sequence CRH (1 μg/kg, maximum 100 μg dose) is used to stimulate corticotrope tumors to secrete ACTH. Most patients with CD respond with an increase in ACTH (>34%) and/or cortisol (>20%) levels within 45 minutes of intravenous administration of ovine CRH (sensitivity 93%). Following administration of human CRH, most CD patients have at least a 14% increase in cortisol levels (sensitivity 85%, specificity 100%). While some reports have shown ovine CRH to be superior to recombinant human CRH, others have found similar responses. A systematic review of all published series on the CRH-stimulation test revealed that 7%-14% of patients with CD fail to respond to CRH. Some patients with ACTH-secreting pulmonary carcinoids (~10%) can respond to dexamethasone and/or CRH.

If the CRH-stimulation test and high-dose DST are both consistent with a pituitary source and imaging studies identify a pituitary lesion consistent with an adenoma (>6 mm), no further testing is necessary. On the other hand, if biochemical testing is discordant and/or the pituitary MRI is normal or equivocal (lesion <6 mm), IPSS with ACTH measurements before and after CRH administration should be performed. A central-to-peripheral ACTH gradient of ≥2.0 before and/or ≥3.0 after CRH administration is consistent with CD. A systematic review of all published studies on IPSS showed an overall sensitivity of 96% and specificity of 100% using these criteria.

Although IPSS is the gold-standard test to distinguish between a pituitary and ectopic source of ACTH, it is an invasive procedure requiring a high degree of skill, and thus is best performed in experienced centers. False-negative IPSS results of 1%-10% have been attributed to anomalous venous drainage, abnormal venous anatomy, lack of expertise, and technical problems. Review of the IPSS venogram and/or prolactin measurement during IPSS can improve diagnostic accuracy and decrease false-negative results. A baseline prolactin inferior petrosal sinus to peripheral (IPS/P) ratio (ipsilateral to the dominant post-CRH ACTH IPS/P ratio) of 1.8 or more suggests successful catheterization during IPSS. Prolactin-normalized ACTH IPS/P ratios can then be used to differentiate between a pituitary and ectopic source of ACTH. Values ≤0.7 suggest EAS, and those ≥1.3 suggest CD. Indeterminate values (0.7–1.3) need further study. False-positive IPSS results can occur in rare cases of ectopic CRH production and in patients with cyclic Cushing’s syndrome if the normal corticotropes are not completely suppressed.

Documentation of sustained hypercortisolism prior to dynamic testing therefore remains crucial.

**Localization of the source of ACTH Cushing’s disease**

As discussed earlier, advanced MRI techniques often do not identify pituitary adenomas. While IPSS localizes the tumor to the pituitary gland, its role in determining the precise tumor location remains controversial. Using an intersinus ratio of 1.4 or more before or after CRH to predict the location of pituitary adenomas, a review of 19 studies (313 cases)
reported poor localizing accuracy (78% overall, 50%–100% in individual studies).\(^{31}\) More recently, Wind et al found that IPSS correctly predicted tumor location in 273 of 396 patients (positive predictive value 69%) with surgically proven CD and a lateral adenoma.\(^{37}\) Mulligan et al demonstrated that the use of prolactin-normalized ACTH intersinus ratios led to improvement in the lateralization accuracy of IPSS (75% versus 54%) in 28 patients with surgically proven CD.\(^{106}\) Although these data are promising, larger prospective studies are needed. Therefore, at present IPSS lateralization results can only be used as a guide for where to begin initial transsphenoidal exploration in MRI negative cases. A thorough exploration of the pituitary gland is essential before using lateralization results for hemihypophysectomy.

**Ectopic ACTH syndrome**

Structural (CT and MRI) and functional (somatostatin scintigraphy and positron emission tomodraphy [PET] scans) imaging studies are used to identify the source of ACTH in EAS, but the optimal imaging strategy has not been well defined. Since no single imaging modality identifies all tumors, correlation of multiple studies is needed.\(^{24,107}\)

Because the majority of these tumors are intrathoracic, initial imaging should focus on the chest, with additional studies obtained as needed. Thin-cut multislice CT scans and 3 T MRI improve tumor detection, but also can give false-positive results.\(^{107}\) As many NETs express somatostatin subtype (sst) receptors, they may be detected via somatostatin scintigraphy (eg, octreotide scan). The ability of these scans to identify a tumor depends on the type (sst1–5) and degree of sst-receptor expression, size of the tumor, and the dose (6–18 mCi pentetreotide) of the radiopharmaceutical and the use of single photon emission CT.\(^{108}\) In vitro studies have shown that glucocorticoids downregulate sst-receptor expression in human neuroendocrine cells.\(^{109}\) This has been described in vivo, as well in two patients with ACTH-secreting pulmonary NETs, where mifepristone (a glucocorticoid receptor antagonist) treatment led to a change in the octreotide-scan status and correct localization of the tumor.\(^{110}\) This phenomenon of improved diagnostic ability of the octreotide scan after medical control of hypercortisolism needs to be further evaluated in larger studies. Ga\(^{68}\)-DOTATATE and DOTATOC, PET radiopharmaceuticals with high affinity for sst2, have shown promise in identifying gastrointestinal–pancreatic and pulmonary NETs. However, patients with ACTH-secreting tumors were not included.\(^{111–113}\) The use of \(^{68}\)Ga-DOTATATE PET scans in identifying the source of ACTH in ectopic Cushing’s syndrome needs further investigation.

As most EAS tumors are slow growing and have low metabolic activity, fluorodeoxyglucose (18F) PET scans have limited utility in tumor localization; they may help define the extent of metastatic disease.\(^{114}\) Radiolabeled L-3,4-dihydroxyphenylalanine and (\(^{11}\)C) 5-hydroxytryptamine PET scans can help with localization.\(^{107,115,116}\) Non-IPSS venous sampling usually does not provide any additional information, and is not considered necessary in the evaluation of ectopic Cushing’s syndrome.\(^{24,117}\)

**Management**

**Surgery**

Surgical resection of the source of glucocorticoid excess (pituitary adenoma, nonpituitary tumor-secreting ACTH or adrenal tumor[s]) remains the first-line treatment of all forms of Cushing’s syndrome. The initial remission rate after transsphenoidal surgery is 60%–80% (<15% in macroadenomas),\(^{118}\) with a relapse rate of up to 20% within 10 years.\(^{119,120}\) However, the success rate depends on the skill and experience of the neurosurgeon, and can be as high as 90% at experienced centers. Patients with hypocortisolism in the immediate postoperative period need glucocorticoid replacement until the recovery of the hypothalamic–pituitary–adrenal axis (usually 6–18 months after surgery).\(^{1}\) Although long-term remission is more likely when postoperative cortisol levels are less than 2 μg/dl. (<54 nmol/L), no cortisol value excludes the possibility of recurrence.\(^{120}\) These data emphasize the need for ongoing surveillance and alternative treatment modalities for CD.

As in CD, surgical removal of an ectopic ACTH-secreting tumor is the optimal treatment. However, occult or metastatic tumors require medical therapy or bilateral adrenalectomy.\(^{24}\)

Laparoscopic unilateral or bilateral adrenalectomy is the treatment of choice in adrenal causes of Cushing’s syndrome, and has an excellent prognosis in benign cases.\(^{121}\) Bilateral adrenalectomy in ACTH-dependent Cushing’s syndrome may be used when surgery and medical therapy are unsuccessful, or based on patient preference. It leads to rapid resolution of hypercortisolemia and related morbidity.\(^{122}\) However, after bilateral adrenalectomy, patients need lifelong glucocorticoid and mineralocorticoid replacement. Another concern with bilateral adrenalectomy in patients with CD is the development of Nelson’s syndrome (local tumor growth with mass effects and increased ACTH levels causing hyperpigmentation). Modern imaging techniques allow early detection and management of corticotrope tumor progression after bilateral adrenalectomy in these patients.\(^{123}\) Some physicians advocate...
prophylactic pituitary radiotherapy to decrease the risk of development of Nelson’s syndrome.\textsuperscript{124}

**Pituitary radiotherapy**

Persistent hypercortisolemia after transsphenoidal surgery due to residual tumor can be treated with radiotherapy. Adjunctive medical control of hypercortisolemia may be needed while awaiting the effects of radiotherapy. Conventional fractionated radiotherapy is very effective, but its effects may be delayed up to 10 years, and it can be associated with long-term hypopituitarism.\textsuperscript{125} Stereotactic radiosurgery is more rapidly effective, but has been associated with a relapse rate of 20%.\textsuperscript{126}

**Medical therapy**

Medical control of hypercortisolemia may be needed in occult cases, while awaiting surgery, when surgery is contraindicated or unsuccessful, and while awaiting the effect of radiation treatment. Medical treatments for hypercortisolemia include agents that inhibit steroidogenesis (ketonozole, metyrapone, mitotane, and etomidate), modulate ACTH release (somatostatin and dopamine agonists) or block glucocorticoid action at its receptor (mifepristone) (Table 3).\textsuperscript{127} A major concern with all medical therapies is the risk of overtreatment and adrenal insufficiency. Medical control of hypercortisolemia can be achieved in two ways: either by blocking cortisol production to achieve normal levels, or by blocking cortisol secretion completely along with glucocorticoid replacement (block and replace). Regardless of the strategy, all patients on medical therapy should be educated about the symptoms of adrenal insufficiency and the emergency use of glucocorticoids.

Ketconazole, a steroidogenesis inhibitor, has a rapid onset of action. It inhibits the first step in cortisol biosynthesis (side-chain cleavage) and to a lesser degree 11\beta-hydroxylase and 17,20-desmolase.\textsuperscript{128} It requires an acidic environment for maximal absorption, and thus has reduced efficacy if used in combination with proton-pump inhibitors. Although used off-label, ketoconazole is usually the first-line agent for medical control of hypercortisolism in the US. However, gastrointestinal side effects, hepatocellular dysfunction, gynecomastia, and decreased libido in men may limit its use.\textsuperscript{129,130} The European Medicines Agency (EMA) has recently withdrawn ketoconazole from the market because of hepatic dyscrasias in patients treated for fungal infections.\textsuperscript{131} A similar safety announcement from the US Food and Drug Administration

**Table 3 Drugs used to treat Cushing’s syndrome: mechanism of action, dosage, and important side effects and concerns**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism of action</th>
<th>Dose</th>
<th>Side effects/concerns</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Steroidogenesis inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>Inhibits CYP11A1 and CYP11B1, other enzymes to lesser extent</td>
<td>400–1,600 mg/day</td>
<td>Hepatotoxicity, GI discomfort, decreased testosterone levels, gynecomastia, adrenal insufficiency; needs gastric acidity for bioavailability</td>
</tr>
<tr>
<td>Metyrapone</td>
<td>Inhibits CYP11B1</td>
<td>500–4,500 mg/day</td>
<td>Dizziness, rash, GI discomfort, acne and hirsutism in women, worsening or new hypertension and hypokalemia, adrenal insufficiency, neutropenia (rarely)</td>
</tr>
<tr>
<td>Mitotane</td>
<td>Adrenolytic, inhibits CYP11A1 and CYP11B1, other possible actions</td>
<td>2–5 g/day</td>
<td>Hepatotoxicity, GI discomfort, hypercholesterolemia, gynecomastia, prolonged bleeding time, dizziness, ataxia, dysarthria, memory loss, adrenal insufficiency; teratogenic, increases CBG</td>
</tr>
<tr>
<td>Etoconitrate</td>
<td>Inhibits CYP11A1 and CYP11B1</td>
<td>0.03–0.3 mg/kg/h</td>
<td>Nephrotoxicity (propylene glycol toxicity), sedation at higher doses, adrenal insufficiency; needs to be initiated in intensive care setting</td>
</tr>
<tr>
<td><strong>Tumor-specific therapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pasireotide</td>
<td>Somatostatin analog (sst5, also sst1–3)</td>
<td>750–2,400 µg/day</td>
<td>Hyperglycemia, GI discomfort, cholestasis, growth-hormone deficiency</td>
</tr>
<tr>
<td>Cabergoline</td>
<td>Dopamine agonist (D\textsubscript{3})</td>
<td>0.5–7 mg/week</td>
<td>Headache, dizziness, GI discomfort, cardiac valve fibrosis at high doses</td>
</tr>
<tr>
<td>Glucocorticoid-receptor antagonist</td>
<td>Reversible blockade of glucocorticoid receptor, antiprogesterin</td>
<td>300–1,200 mg/day</td>
<td>Hypokalemia, worsening hypertension, adrenal insufficiency, endometrial hyperplasia, GI discomfort; cortisol levels cannot be used to titrate therapy</td>
</tr>
<tr>
<td><strong>Other potential agents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinoic acid</td>
<td>Inhibits POMC transcription and ACTH secretion</td>
<td>10–80 mg/day</td>
<td>Conjunctival irritation, nausea, arthralgias, headache</td>
</tr>
<tr>
<td>LCI699</td>
<td>Inhibits CYP11B1</td>
<td>4–100 mg/day</td>
<td>Fatigue, nausea, diarrhea, headache, adrenal insufficiency</td>
</tr>
<tr>
<td>Gefinitib</td>
<td>Tyrosine-kinase inhibitor that targets EGFR</td>
<td></td>
<td>Rash, pruritus, GI discomfort, peripheral edema; only in vitro and animal data available, has not been tested in humans</td>
</tr>
</tbody>
</table>

**Abbreviations:** ACTH, adrenocorticotropic hormone; CBG, corticosteroid-binding globulin; CYP, cytochrome P450; CYP11A1, cholesterol side-chain cleavage enzyme; CYP11B1, 11\beta-hydroxylase; D\textsubscript{3}, dopamine receptor subtype 2; EGFR, epidermal growth factor receptor; GI, gastrointestinal; POMC, proopiomelanocortin; sst, somatostatin-receptor subtype.
Metyrapone inhibits 11β-hydroxylase and has a rapid onset of action. In the US, it is primarily used as adjunctive therapy with other steroidogenesis inhibitors and with radiation therapy in CD. Increased deoxycorticosterone levels, due to inhibition of 11β-hydroxylase by metyrapone, can lead to salt retention and (rarely) hypertension, while increased adrenal androgens can lead to new or worsening hirsutism and acne in women. Both ketoconazole and metyrapone have been associated with an increase in ACTH secretion and loss of control of hypercortisolism over time in CD (escape phenomena).

Metyrapone, another steroidogenesis inhibitor, is also adrenolytic. It has a slow-onset, long-lasting action. Metyrapone increases CBG levels, leading to falsely high total cortisol levels, complicating titration of therapy. It is teratogenic, not well tolerated, and is primarily used in the treatment of adrenocortical carcinoma. During treatment, plasma metyrapone concentrations must be monitored. Etomidate is a substituted imidazole anesthetic agent that inhibits 11β-hydroxylase. It has been used for rapid control of hypercortisolism in hospitalized patients in an intensive care unit setting, and is the only available intravenous parenteral agent.

Recently, somatostatin (sst5 and sst2) and dopamine (D2) receptors have been identified as therapeutic targets in CD. Pituitary-directed therapy with pasireotide (a somatostatin analog with high affinity for sst1, -2, -3, and -5) or cabergoline (a dopamine agonist) normalizes UFC in 20%–40% of patients with CD. This represents an off-label use for cabergoline. Pasireotide (Signifor), the first agent approved by the EMA and FDA for the treatment of patients who have failed surgery or are not surgical candidates, is most effective when UFC is less than twice the upper limit of normal. Seventy-three percent of patients treated with pasireotide develop glucose intolerance due to inhibition of incretin secretion, with a concomitant decrease in insulin secretion. Glucagon-like peptide-1 agonists or dipeptidyl peptidase-4 inhibitors can effectively control glucose levels in this setting.

Mifepristone (RU-486, Korlym), a glucocorticoid and progesterone-receptor antagonist, has been approved in the US for control of hyperglycemia secondary to hypercortisolism in patients with Cushing’s syndrome who have failed surgery or are not surgical candidates. It has a rapid onset of action, and can be used to treat acute complications of Cushing’s syndrome, especially cortisol-induced psychosis. It is important to note that cortisol and ACTH levels remain unchanged or increase with the use of mifepristone, and cannot be used to gauge treatment success or to diagnose adrenal insufficiency. Moreover, increases in ACTH and cortisol levels can lead to (worsening of) mineralocorticoid effects (hypertension, edema, hypokalemia), and women can develop endometrial thickening during prolonged treatment.

Other agents currently under (preclinical) study for the medical control of hypercortisolism include LCI699 (an 11β-hydroxylase inhibitor), retinoic acid, and gefitinib (tyrosine-kinase inhibitor with EGFR [epidermal growth factor receptor] as target) (Table 3).

Combination therapy with different agents may be needed to achieve normal plasma cortisol levels in patients with moderate-to-severe hypercortisolism. This can reduce drug-related adverse events if lower combined doses are effective. A small study of 17 patients showed an overall response rate of 88% after sequential addition of ketoconazole and/or cabergoline when initial pasireotide therapy was not successful. Overall, medical treatment in Cushing’s syndrome needs to be individualized according to patient characteristics, potential side effects, and other pharmacological properties of the drugs.

Conclusion
Cushing’s syndrome, a rare disorder, is associated with significant morbidity and mortality. Clinical presentation can be broad, and establishing the diagnosis can be difficult. Early recognition and rapid control of hypercortisolism is necessary to decrease morbidity and mortality in these patients. Surgery remains the optimal treatment in all forms of Cushing’s syndrome, but may not be curative. Individualized medical treatment and a multidisciplinary approach are needed for optimal control of hypercortisolism and management of comorbidities. New alternative modalities of medical treatment are needed.

Disclosure
STS reports no conflicts of interest in this work. LKN has received funding from Laboratoire-HRA Pharma as part of a Cooperative Research and Development Agreement to conduct research on the antiglucocorticoid agent, mifepristone. RAF has received research grants from Novartis.

References


